公开(公告)号：US12029749B2

公开(公告)日：2024-07-09

申请号：US17010648

申请日：2020-09-02

Applicant: TARIS Biomedical LLC

Inventor： Dennis Giesing ,  Christopher Cutie

IPC: A61K31/7068 ,  A61K9/00 ,  A61K9/06 ,  A61K47/36 ,  A61P13/10 ,  A61P31/04 ,  A61P35/00 ,  C07H19/06

CPC classification number: A61K31/7068 ,  A61K9/0034 ,  A61K9/06 ,  A61K47/36 ,  A61P13/10 ,  A61P31/04 ,  A61P35/00 ,  C07H19/06

Abstract: Provided are methods of treating urothelial carcinomas of the lower tract comprising administering comprising administering gemcitabine continuously and locally to the bladder of an individual in an induction therapy and/or maintenance therapy.

公开(公告)号：US20240209010A1

公开(公告)日：2024-06-27

申请号：US18278530

申请日：2022-02-24

Applicant: KASHIV BIOSCIENCES, LLC

Inventor： Parva Yogeshchandra PUROHIT ,  Ganesh Vishwanath SANGLE ,  Vishal Bharatbhai UNADKAT ,  Vishalgiri Gunvantgiri GOSWAMI ,  Heta Nishil PANDYA ,  Chirag Chimanlal MEHTA

IPC: C07F9/58 ,  A61K31/4427 ,  A61K31/675 ,  A61P13/10 ,  A61P25/04 ,  C07D213/85 ,  C07D401/12 ,  C07D401/14 ,  C07D471/10 ,  C07D487/10

CPC classification number: C07F9/58 ,  A61K31/4427 ,  A61K31/675 ,  A61P13/10 ,  A61P25/04 ,  C07D213/85 ,  C07D401/12 ,  C07D401/14 ,  C07D471/10 ,  C07D487/10

Abstract: The present invention relates to compounds of formula I and therapeutic use of the same. The present invention also discloses pharmaceutical composition of compounds of formula I and method of treatment using the same.

公开(公告)号：US11905270B2

公开(公告)日：2024-02-20

申请号：US16472118

申请日：2017-12-18

Applicant: Bayer Pharma Aktiengesellschaft

Inventor： Stefan Baeurle ,  Adam James Davenport ,  Christopher Stimson ,  Jens Nagel ,  Nicole Schmidt ,  Andrea Rotgeri ,  Ina Groeticke ,  Alexandra Rausch ,  Juergen Klar ,  Thomas Dyrks

IPC: C07D333/28 ,  A61P13/10 ,  C07D231/12 ,  C07D231/56 ,  C07D495/04 ,  C07D333/38 ,  C07D233/64 ,  C07D405/04 ,  C07D277/56 ,  C07D241/12 ,  C07D333/58 ,  A61P3/04 ,  A61P3/10 ,  A61P35/00 ,  A61P19/02 ,  C07D213/56 ,  C07D231/16

CPC classification number: C07D333/28 ,  A61P3/04 ,  A61P3/10 ,  A61P13/10 ,  A61P19/02 ,  A61P35/00 ,  C07D213/56 ,  C07D231/12 ,  C07D231/56 ,  C07D233/64 ,  C07D241/12 ,  C07D277/56 ,  C07D333/38 ,  C07D333/58 ,  C07D405/04 ,  C07D495/04

Abstract: The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a diseaseas a sole agent or in combination with other active ingredients.

公开(公告)号：US11786604B2

公开(公告)日：2023-10-17

申请号：US16878010

申请日：2020-05-19

Applicant: Birdie Biopharmaceuticals, Inc.

Inventor： Lixin Li

IPC: A61K47/68 ,  C07K16/32 ,  A61K45/06 ,  A61K39/00 ,  A61P13/10 ,  A61P43/00 ,  A61P13/08 ,  A61P35/00

CPC classification number: A61K47/6803 ,  A61K45/06 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6863 ,  A61K47/6871 ,  A61K47/6889 ,  C07K16/32 ,  A61K2039/505 ,  A61P13/08 ,  A61P13/10 ,  A61P35/00 ,  A61P43/00 ,  C07K2317/24 ,  C07K2317/732

Abstract: The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of HER2 positive tumors/cancers.

公开(公告)号：US20230270713A1

公开(公告)日：2023-08-31

申请号：US18008947

申请日：2021-06-18

Applicant: Sorrento Therapeutics, Inc.

Inventor： Alexis Nahama ,  Henry Hongjun Ji

IPC: A61K31/357 ,  A61K47/26 ,  A61P35/00 ,  A61P13/10

CPC classification number: A61K31/357 ,  A61K47/26 ,  A61P35/00 ,  A61P13/10

Abstract: Disclosed herein are methods of administering resiniferatoxin (RTX) intravesically for treatment of bladder pain, and compositions for use in such methods.

公开(公告)号：US20230255897A1

公开(公告)日：2023-08-17

申请号：US18119673

申请日：2023-03-09

Applicant: Panag Pharma Inc.

Inventor： Melanie Kelly ,  Christian Lehmann ,  Mary Lynch

IPC: A61K31/015 ,  A61K31/10 ,  A61P13/10 ,  A61K9/00 ,  A61K9/08

CPC classification number: A61K31/015 ,  A61K31/10 ,  A61P13/10 ,  A61K9/0053 ,  A61K9/0014 ,  A61K9/08

Abstract: The present application relates to methods and uses of CB2 target agent local anaesthetics such as beta-caryophyllene for treatment of interstitial cystitis in a subject, optionally together with the administration or use of an additional agent for treating interstitial cystitis such as dimethyl sulfoxide (DMSO) or methylsulfonylmethane (MSM).

公开(公告)号：US20230190948A1

公开(公告)日：2023-06-22

申请号：US18095753

申请日：2023-01-11

Applicant: Cornell University ,  Tu Therapeutics Inc.

Inventor： Shek Hang Benedict Law ,  Vanessa Bellat ,  Benjamin Byung-min Choi

IPC: A61K47/65 ,  A61P13/10 ,  A61P35/00 ,  A61K45/06 ,  A61K47/18

CPC classification number: A61K47/65 ,  A61K45/06 ,  A61K47/183 ,  A61P13/10 ,  A61P35/00

Abstract: The present disclosure relates to a systemically administered peptide delivery platform that biodistributes to the kidney or urinary tract. The disclosure further relates to methods of treating a disease of the kidney or urinary tract in a subject in need thereof.

公开(公告)号：US20230181628A1

公开(公告)日：2023-06-15

申请号：US17999347

申请日：2021-05-19

Applicant: OSAKA UNIVERSITY

Inventor： Kazutake TSUJIKAWA ,  Kiyoto TAKAMORI ,  Takekatsu SHIBATA

IPC: A61K33/14 ,  A61P35/00 ,  A61P13/10 ,  A61K31/14 ,  A61P15/00 ,  A61P1/00 ,  A61P1/18

CPC classification number: A61K33/14 ,  A61P35/00 ,  A61P13/10 ,  A61K31/14 ,  A61P15/00 ,  A61P1/00 ,  A61P1/18

Abstract: The present invention provides an epithelial cancer therapeutic agent with less side effects. In order to achieve the above object, an epithelial cancer therapeutic agent of the present invention includes: at least one material selected from the group consisting of oxo acid, oxo acid ion, and oxo acid salt, wherein the epithelial cancer therapeutic agent treats or prevents epithelial cancer.

公开(公告)号：US20190023657A1

公开(公告)日：2019-01-24

申请号：US16138369

申请日：2018-09-21

Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.

Inventor： Fumihiko SAITOH ,  Hiroshi NAGASUE

IPC: C07D213/75 ,  A61K45/06 ,  A61K31/4418 ,  C07D401/04 ,  A61K31/506 ,  A61K31/4439 ,  A61K31/444 ,  C07D213/84 ,  C07D405/04 ,  A61K31/4433 ,  C07D405/14 ,  C07D213/81 ,  C07D413/12 ,  C07D417/04

CPC classification number: C07D213/75 ,  A61K31/4418 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/506 ,  A61K45/06 ,  A61P1/00 ,  A61P1/02 ,  A61P1/04 ,  A61P1/16 ,  A61P1/18 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P5/14 ,  A61P7/00 ,  A61P9/00 ,  A61P9/06 ,  A61P9/12 ,  A61P11/00 ,  A61P11/02 ,  A61P11/04 ,  A61P11/06 ,  A61P13/02 ,  A61P13/08 ,  A61P13/10 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P19/02 ,  A61P19/10 ,  A61P21/00 ,  A61P21/02 ,  A61P25/00 ,  A61P25/04 ,  A61P25/08 ,  A61P25/16 ,  A61P25/20 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P29/02 ,  A61P31/00 ,  A61P31/18 ,  A61P35/00 ,  A61P35/02 ,  A61P37/00 ,  A61P37/06 ,  A61P43/00 ,  C07B2200/07 ,  C07C215/44 ,  C07C271/24 ,  C07C2602/10 ,  C07D213/81 ,  C07D213/84 ,  C07D401/04 ,  C07D405/04 ,  C07D405/14 ,  C07D413/12 ,  C07D417/04

Abstract: The present invention aims to provide a compound having a TrkA inhibitory action, a pharmaceutically acceptable salt thereof, or a solvate thereof, a pharmaceutical composition containing the same as an active ingredient, and a preventive and/or therapeutic agent for medicinal use, in particular for a disease in which TrkA in involved (pain, cancers, inflammation/inflammatory diseases, allergic diseases, skin diseases, neurodegenerative diseases, infectious diseases, Sjogren's syndrome, endometriosis, renal diseases, osteoporosis, and the like). Specifically, the present invention provides a compound or an optical isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or the like, the compound represented by formula (I):

公开(公告)号：US20170157100A1

公开(公告)日：2017-06-08

申请号：US15369417

申请日：2016-12-05

Applicant: Sidney J. Goldfarb

Inventor： Sidney J. Goldfarb

IPC: A61K31/445 ,  A61K45/06 ,  A61K31/195

CPC classification number: A61K31/445 ,  A61K31/27 ,  A61K45/06 ,  A61P13/00 ,  A61P13/02 ,  A61P13/10 ,  A61K2300/00

Abstract: A method of treating one or more symptoms associated with underactive bladder in a patient suffering therefrom by administering to the patient a therapeutically effective amount of an acetylcholinesterase inhibitor (AChEI) and an amount of a muscarinic receptor agonist effective to reduce the volume of post void residual in the patient obtained by treatment with the AChEI alone.